NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 3 October 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice Chair) Present for all items
3. Alan Thomas Present for all items
4. Ana Duarte Present for all items
5. Andrew Champion Present for all items
6. Becky Pennington Present for all items
7. Dominic Pivonka Present for all items
8. Dr Fiona MacPherson Smith Present for all items
9. Prof. G.J. Melendez-Torres Present for all items
10. Hugo Pedder Present for all items
11. Jaqueline Tomlinson Present for all items
12. Dr Justin Daniels Present for all items
13. Dr Peter Baker Present for items 1.1 to 5.3.3
14. Min Ven Teo Present for items 1.1 to 5.3.3
15. Mohamad Farhat Present for all items
16. Dr Mohit Sharma Present for all items
17. Dr Patrick De Barr Present for all items
18. Dr Pratheeban Nambyiah Present for all items
19. Ravi Ramessur Present for all items
20. Richard Ballerand Present for all items
21. Dr Steve Edwards Present for all items

NICE staff present

Ian Watson, Associate Director Present for items 1.1 to 3.3.2

Janet Roberson, Associate Director Present for items 5.1 to 6.3.2

Jeremy Powell, Project Manager Present for items 1.1 to 3.3.2

Thomas Feist, Project Manager Present for items 5.1 to 6.3.2

Marcela Haasova, Technical Advisor Present for items 1.1 to 3.3.2

Ewa Rupniewska, Technical Analyst Present for items 1.1 to 3.3.2

Joanna Richardson, Technical Advisor Present for items 5.1 to 5.3.2

Emilene Coventry, Technical Analyst Present for items 5.1 to 5.3.2

Zoe Charles, Technical Advisor Present for items 6.1 to 6.3.2

Alexandra Sampson, Technical Analyst Present for items 6.1 to 6.3.2

External assessment group representatives present

James Mahon, Liverpool Reviews and Implementation Group Present for items 1.1 to 4.1.3

Samuel Bryning, Liverpool Reviews and Implementation Group Present for items 1.1 to 4.1.3

Angela Stainthorpe, Liverpool Reviews and Implementation Group

 Present for items 5.1 to 5.1.3

Rebecca Bresnahan, Liverpool Reviews and Implementation Group

 Present for items 5.1 to 5.1.3

Rob Hodgson, University of York Present for items 6.1 to 6.1.3

Mark Rodgers, University of York Present for items 6.1 to 6.1.3

Experts present

Peter Clark, NHS England CDF clinical lead Present for items 1.1 to 6.3.2

Helen Stewart, Patient Expert nominated by MET UP UK

 Present for items 1.1 to 4.1.3

Holly Heath, Patient Expert nominated by Breast Cancer Now Present for items 1.1 to 4.1.3

Dr Jennifer Glendenning, Clinical Expert nominated by Royal College of Physicians Present for items 1.1 to 4.1.3

Heather Shaw, Consultant Medical Oncologist, Clinical expert nominated by BMS Present for items 5.1 to 5.1.3

Mark Harries, Consultant in Medical Oncology, Clinical expert nominated by Melanoma Focus Present for items 5.1 to 5.1.3

Jonathan Haines, Patient expert, nominated by Melanoma Focus Present for items 5.1 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Craig Buckley.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 5 September 2023
1. Topic 1: [talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations [ID1342]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10366)
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10366)
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by James Fotheringham.
	2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10366>
1. Topic 2: [Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10581)
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external assessment group representatives, and company representatives from BMS.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10581)
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Patrick Barr (Clinical), Hugo Pedder (Cost), Alan Thomas (Lay).
	2. Part 2 - Closed session (company representatives, clinical experts, and external assessment group representatives were asked to leave the meeting).
		1. The committee will consider additional analysis on 7 November 2023
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10581>.
1. Topic 3: [Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer [ID6279]](https://www.nice.org.uk/guidance/ta885)
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external assessment group representatives, and company representatives from MSD.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/ta885)
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
	2. Part 2 – Closed session (company representatives and external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/ta885>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 7th November 2023 and will start promptly at 9:00am.